A propensity-score-matched analysis of laparoscopic vs open surgery for rectal cancer in a population-based study.


Journal

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611

Informations de publication

Date de publication:
04 2019
Historique:
received: 19 09 2018
accepted: 11 12 2018
pubmed: 27 12 2018
medline: 25 9 2020
entrez: 27 12 2018
Statut: ppublish

Résumé

The oncological risk/benefit trade-off for laparoscopy in rectal cancer is controversial. Our aim was to compare laparoscopic vs open surgery for resection of rectal cancer, using unselected data from the public healthcare system of Catalonia (Spain). This was a multicentre retrospective cohort study of all patients who had surgery with curative intent for primary rectal cancer at Catalonian public hospitals from 2011 to 2012. We obtained follow-up data for up to 5 years. To minimize the differences between the two groups, we performed propensity score matching on baseline patient characteristics. We used multivariate Cox proportional hazards regression analyses to assess locoregional relapse at 2 years and death at 2 and 5 years. Of 1513 patients with Stage I-III rectal cancer, 933 (61.7%) had laparoscopy (conversion rate 13.2%). After applying our propensity score matching strategy (2:1), 842 laparoscopy patients were matched to 517 open surgery patients. Multivariate Cox analysis of death at 2 years [hazard ratio (HR) 0.65, 95% CI 0.48, 0.87; P = 0.004] and 5 years (HR 0.61, 95% CI 0.5, 0.75; P < 0.001) and of local relapse at 2 years (HR 0.44, 95% CI 0.27, 0.72; P = 0.001) showed laparoscopy to be an independent protective factor compared with open surgery. Laparoscopy results in lower locoregional relapse and long-term mortality in rectal cancer in unselected patients with all-risk groups included. Studies using long-term follow-up of cohorts and unselected data can provide information on clinically relevant outcomes to supplement randomized controlled trials.

Identifiants

pubmed: 30585686
doi: 10.1111/codi.14545
doi:

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

441-450

Informations de copyright

Colorectal Disease © 2018 The Association of Coloproctology of Great Britain and Ireland.

Auteurs

P Manchon-Walsh (P)

Catalonian Cancer Strategy, Department of Health, Government of Catalonia, Barcelona, Spain.
Biomedical Research Institute of Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.

L Aliste (L)

Catalonian Cancer Strategy, Department of Health, Government of Catalonia, Barcelona, Spain.
Biomedical Research Institute of Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.

S Biondo (S)

Biomedical Research Institute of Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.
Department of General and Digestive Surgery Colorectal Unit, Bellvitge University Hospital, Barcelona, Spain.

E Espin (E)

Colorectal Surgery Unit, Vall d'Hebron University Hospital, Barcelona, Spain.

M Pera (M)

Colorectal Surgery Unit, Department of Surgery, Hospital del Mar (IMIM), Barcelona, Spain.

E Targarona (E)

Colorectal Surgery Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

N Pallarès (N)

Statistics Advisory Service, Biomedical Research Institute of Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.
Basic Clinical Practice Department, University of Barcelona, Barcelona, Spain.

R Vernet (R)

Biomedical Research Institute of Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.
University School of Nursing and Occupational Therapy (EUIT), Autonomous University of Barcelona, Barcelona, Spain.

J A Espinàs (JA)

Catalonian Cancer Strategy, Department of Health, Government of Catalonia, Barcelona, Spain.
Biomedical Research Institute of Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.

A Guarga (A)

Health Service Procurement and Assessment, Catalonian Health Service (CatSalut), Barcelona, Spain.

J M Borràs (JM)

Catalonian Cancer Strategy, Department of Health, Government of Catalonia, Barcelona, Spain.
Biomedical Research Institute of Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH